Arrowhead Pharma Files 8-K: Board & Executive Compensation Changes
Ticker: ARWR · Form: 8-K · Filed: Feb 7, 2025 · CIK: 879407
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
Related Tickers: ARWR
TL;DR
Arrowhead Pharma (ARWR) filed an 8-K detailing board changes and executive comp updates.
AI Summary
Arrowhead Pharmaceuticals, Inc. announced on February 7, 2025, changes in its board of directors and executive compensation. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its named executive officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive and board positions can introduce uncertainty regarding future strategy and leadership.
Key Players & Entities
- Arrowhead Pharmaceuticals, Inc. (company) — Registrant
- February 7, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 177 E. Colorado Blvd , Suite 700 , Pasadena , CA 91105 (address) — Principal Business Address
FAQ
What specific items are covered in this 8-K filing by Arrowhead Pharmaceuticals?
This 8-K filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 7, 2025.
What is Arrowhead Pharmaceuticals, Inc.'s state of incorporation?
Arrowhead Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal business address of Arrowhead Pharmaceuticals, Inc.?
The principal business address is 177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105.
What is the SIC code for Arrowhead Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Arrowhead Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 973 words · 4 min read · ~3 pages · Grade level 12.2 · Accepted 2025-02-06 18:58:19
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ARWR The Nasdaq Global Select
- $771,200 — ant of restricted stock units valued at $771,200. These restricted stock units are sched
Filing Documents
- arwr-20250207.htm (8-K) — 32KB
- 0001628280-25-004313.txt ( ) — 158KB
- arwr-20250207.xsd (EX-101.SCH) — 2KB
- arwr-20250207_lab.xml (EX-101.LAB) — 22KB
- arwr-20250207_pre.xml (EX-101.PRE) — 13KB
- arwr-20250207_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: February 7, 2025 ARROWHEAD PHARMACEUTICALS, INC. By: /s/ Kenneth Myszkowski Kenneth Myszkowski Chief Financial Officer